AMRX
NASDAQ · Pharmaceuticals
Amneal Pharmaceuticals Inc
$14.64
+0.04 (+0.27%)
Financial Highlights (FY 2026)
Revenue
2.83B
Net Income
-118,598,566
Gross Margin
36.5%
Profit Margin
-4.2%
Rev Growth
+10.1%
D/E Ratio
136.58
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 36.5% | 36.5% | 31.8% | 31.8% |
| Operating Margin | 8.9% | 8.0% | 35.6% | 35.2% |
| Profit Margin | -4.2% | -4.0% | 34.4% | 33.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.83B | 2.57B | 607.96M | 566.33M |
| Gross Profit | 1.04B | 940.33M | 193.42M | 180.17M |
| Operating Income | 252.87M | 206.71M | 216.47M | 199.53M |
| Net Income | -118,598,566 | -96,947,056 | 209.30M | 189.93M |
| Gross Margin | 36.5% | 36.5% | 31.8% | 31.8% |
| Operating Margin | 8.9% | 8.0% | 35.6% | 35.2% |
| Profit Margin | -4.2% | -4.0% | 34.4% | 33.5% |
| Rev Growth | +10.1% | +10.1% | -4.4% | -5.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 2.28B | 2.28B | 254.87M | 263.92M |
| Total Equity | 16.68M | 16.68M | 2.84B | 2.75B |
| D/E Ratio | 136.58 | 136.58 | 0.09 | 0.10 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 453.17M | 391.02M | 317.16M | 296.42M |
| Free Cash Flow | — | — | 187.04M | 181.02M |